Vivek Subbiah M.D.

Vivek Subbiah, MD has a diverse and extensive work experience in the field of oncology research and drug development. Vivek is currently serving as the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute since 2023.

Prior to that, Dr. Subbiah held multiple roles at MD Anderson Cancer Center, including Executive Director of Oncology Research for the MD Anderson Cancer Network from 2019 to 2023. In this role, they collaborated with hospitals and health systems to improve the quality and accessibility of cancer care and research.

Vivek also worked as an Associate Professor in the Department of Investigational Cancer Therapeutics and as the Medical Director of the Clinical Center for Targeted Therapy at MD Anderson. These roles focused on expedited translation of novel cancer treatments from the laboratory to clinical trials.

Before joining MD Anderson, Dr. Subbiah completed clinical fellowships in adult medical oncology and pediatric hematology and oncology. Vivek also pursued a clinical residency in combined internal medicine and pediatrics at Case Western Reserve University.

Vivek Subbiah, MD began their education in 1996 at Sri Ramachandra Medical College and Research Institute. Vivek pursued an MD in Medicine and successfully completed their degree in 2003.